Cargando…

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials

INTRODUCTION: Anemia frequently occurs in chronic kidney disease (CKD), is associated with poor quality of life and cardiovascular outcomes, and its treatment represents a considerable economic burden to the healthcare system. Although effective, the current standard of care for the treatment of ane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwal, Rajiv, Anand, Sanjeev, Eckardt, Kai-Uwe, Luo, Wenli, Parfrey, Patrick S., Sarnak, Mark J., Solinsky, Christine M., Vargo, Dennis L., Winkelmayer, Wolfgang C., Chertow, Glenn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Patient-Oriented, Translational Research: Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909618/ https://www.ncbi.nlm.nih.gov/pubmed/36450264 http://dx.doi.org/10.1159/000528443

Ejemplares similares

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
por: Koury, Mark J., et al.
Publicado: (2022)

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis
por: Sarnak, Mark J, et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Treated Patients
por: Parfrey, Patrick S., et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Naïve Patients
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2023)

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO(2)VATE trials
por: Eckardt, Kai-Uwe, et al.
Publicado: (2020)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
por: Gang, Sishir, et al.
Publicado: (2022)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe
por: Deger, Melike, et al.
Publicado: (2012)

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
por: Platzbecker, U, et al.
Publicado: (2017)

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania
por: Berbec, Nicoleta Mariana, et al.
Publicado: (2018)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022)

Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients
por: Dekker, Shosha E.I., et al.
Publicado: (2022)

Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
por: Cherney, David Z.I., et al.
Publicado: (2022)

Trends in Adherence to Recommended Physical Activity and Its Association with Mortality and Disease Progression among US Adults with Chronic Kidney Disease
por: Qu, Xiaolin, et al.
Publicado: (2022)

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes
por: An, Jaejin, et al.
Publicado: (2023)

Interleukin-6-to-Albumin Ratio as a Superior Predictor of Mortality in End-Stage Kidney Disease Patients
por: Li, Xiejia, et al.
Publicado: (2023)

Association of Self-Reported Nighttime Sleep Duration with Chronic Kidney Disease: China Health and Retirement Longitudinal Study
por: Jiang, Bingxin, et al.
Publicado: (2023)

Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes
por: Connelly, Philip W., et al.
Publicado: (2009)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
por: Deshmukh, Harshal A., et al.
Publicado: (2012)

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity
por: Rubinow, Katya B., et al.
Publicado: (2012)

Intake levels of dietary long-chain PUFAs modify the association between genetic variation in FADS and LDL-C
por: Hellstrand, S., et al.
Publicado: (2012)

Plasma apolipoprotein O level increased in the patients with acute coronary syndrome
por: Yu, Bi-lian, et al.
Publicado: (2012)

Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects
por: Ooi, Esther M. M., et al.
Publicado: (2012)

Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
por: Shearer, Gregory C., et al.
Publicado: (2012)

Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis
por: Gaspar, Paulo, et al.
Publicado: (2014)

New insights regarding tissue Se and Hg interactions on oxidative stress from plasma IsoP and IsoF measures in the Canadian Inuit population
por: Alkazemi, Dalal, et al.
Publicado: (2013)

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
por: Meikle, Peter J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9fd8qmlblbm2cp2rtuoimngjp8